Literature DB >> 6256003

Purification and characterization of a plasminogen activator from mouse cells transformed by an oncogenic virus.

K Danø, V Moller, L Ossowski, L S Nielsen.   

Abstract

On the basis of cellular morphology, a subline of mouse sarcoma virus-infected 3T3 cells was selected which released a 48 000-dalton plasminogen activator at an approx. 40-fold higher rate than those of the parent line, and which continued to do so for several months when the cells were maintained in serum-free culture medium. Culture medium (3.5 l) containing 0.6 mg plasminogen activator per l was used to purify 620 micrograms of the enzyme 130-fold with a yield of 32% by affinity chromatography followed by anion exchange chromatography and gel filtration. Crucial for the yield was the use of a non-ionic detergent and of inhibitors of proteolysis to prevent adsorption and degradation, respectively. The purified enzyme was homogeneous as evaluated by SDS-polyacrylamide gel electrophoresis and had an isoelectric point of pH 9.2. The purified enzyme showed characteristics of a trypsin-like serine protease (labeling with [3H]diisopropylphosphorofluoridate which was prevented by p-nitrophenyl-p'-guanidinobenzoate) and converted the single chain of human plasminogen into two chains of plasmin with electrophoretic mobilities identical to those of the chains formed by non-purified enzyme and by human urokinase. In the absence of inhibitors, solutions of purified enzyme were stable for 24 h at 4 degrees C at pH 3-9.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6256003     DOI: 10.1016/0005-2744(80)90110-2

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  Rapid neural regulation of muscle urokinase-like plasminogen activator as defined by nerve crush.

Authors:  D Hantaï; J S Rao; B W Festoff
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

2.  Tissue-type plasminogen activator in rat adrenal medulla.

Authors:  P Kristensen; D M Hougaard; L S Nielsen; K Danø
Journal:  Histochemistry       Date:  1986

3.  Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma.

Authors:  P Kristensen; C Pyke; L R Lund; P A Andreasen; K Danø
Journal:  Histochemistry       Date:  1990

4.  Purification and characterization of a plasminogen activator secreted by a pig kidney cell line.

Authors:  M Sudol; E Reich
Journal:  Biochem J       Date:  1984-05-01       Impact factor: 3.857

5.  Increased activity of plasminogen activators during involution of the rat ventral prostate.

Authors:  P S Rennie; R Bouffard; N Bruchovsky; H Cheng
Journal:  Biochem J       Date:  1984-07-01       Impact factor: 3.857

6.  Tissue plasminogen activator (t-PA) production by a high density culture of weakly adherent human embryonic kidney cells using a polyurethane-foam packed-bed culture system.

Authors:  Y Kawakubo; T Matsushita; K Funatsu
Journal:  Appl Microbiol Biotechnol       Date:  1994-06       Impact factor: 4.813

7.  Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme.

Authors:  K Kaltoft; L S Nielsen; J Zeuthen; K Danø
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

8.  Monoclonal antibody to human 66,000 molecular weight plasminogen activator from melanoma cells. Specific enzyme inhibition and one-step affinity purification.

Authors:  L S Nielsen; J G Hansen; P A Andreasen; L Skriver; K Danø; J Zeuthen
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

9.  Inactive proenzyme to tissue-type plasminogen activator from human melanoma cells, identified after affinity purification with a monoclonal antibody.

Authors:  P A Andreasen; L S Nielsen; J Grøndahl-Hansen; L Skriver; J Zeuthen; R W Stephens; K Danø
Journal:  EMBO J       Date:  1984-01       Impact factor: 11.598

10.  Tumor promoter PMA stimulates the synthesis and secretion of mouse pro-urokinase in MSV-transformed 3T3 cells: this is mediated by an increase in urokinase mRNA content.

Authors:  D Belin; F Godeau; J D Vassalli
Journal:  EMBO J       Date:  1984-08       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.